GE ships one-thousandth Prodigy
The market for bone densitometry has retreated from its heyday of a few years back, but sales have been strong enough to propel GE Medical Systems’ Lunar to a new milestone. The company has shipped 1000 units of its bone densitometer, Prodigy. The
The market for bone densitometry has retreated from its heyday of a few years back, but sales have been strong enough to propel GE Medical Systems’ Lunar to a new milestone. The company has shipped 1000 units of its bone densitometer, Prodigy. The product was introduced in late 1998. Primary customers have been radiologists, orthopedists, and endocrinologists, as well as primary-care physicians and ob/gyns. Most of those units were sold when Lunar operated as an independent, publicly traded company. Lunar was acquired by GE in late 2000.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
